{"id":747811,"date":"2023-04-14T12:00:17","date_gmt":"2023-04-14T16:00:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/"},"modified":"2023-04-14T12:00:17","modified_gmt":"2023-04-14T16:00:17","slug":"investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/","title":{"rendered":"Investigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC"},"content":{"rendered":"
\n

ATLANTA, April 14, 2023 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether Sarepta Therapeutics, Inc. (\u201cSarepta Therapeutics\u201d\u202for the \u201cCompany\u201d) (NASDAQ: SRPT) complied with federal securities laws. On March 16, 2023, Sarepta Therapeutics announced that \u201cat its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration\u2019s Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date.\u201d Following this announcement, the price of the Company\u2019s stock dropped.<\/p>\n

If you purchased Sarepta Therapeutics stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Marshall Dees, Esq. at\u202f mdees@holzerlaw.com<\/a> or Joshua Karr, Esq. at\u202fjkarr@holzerlaw.com<\/u><\/a>, call our toll-free number at (888) 508-6832, or visit our website at https:\/\/holzerlaw.com\/case\/sarepta-therapeutics\/<\/a> to discuss your legal rights.<\/p>\n

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.\u202fMore information about the firm is available through its website, www.holzerlaw.com<\/u><\/a>,\u202fand upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.\u202f\u00a0<\/p>\n

CONTACT:\u202f\u00a0
Marshall Dees, Esq.\u202f\u00a0
(888) 508-6832 (toll-free)\u202f\u00a0
mdees@holzerlaw.com<\/a><\/p>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ATLANTA, April 14, 2023 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether Sarepta Therapeutics, Inc. (\u201cSarepta Therapeutics\u201d\u202for the \u201cCompany\u201d) (NASDAQ: SRPT) complied with federal securities laws. On March 16, 2023, Sarepta Therapeutics announced that \u201cat its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration\u2019s Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date.\u201d Following this announcement, the price of the Company\u2019s stock dropped. If you purchased Sarepta Therapeutics stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Marshall Dees, Esq. at\u202f mdees@holzerlaw.com or Joshua Karr, Esq. at\u202fjkarr@holzerlaw.com, call our … <\/p>\n

Continue reading “Investigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-747811","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nInvestigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, April 14, 2023 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether Sarepta Therapeutics, Inc. (\u201cSarepta Therapeutics\u201d\u202for the \u201cCompany\u201d) (NASDAQ: SRPT) complied with federal securities laws. On March 16, 2023, Sarepta Therapeutics announced that \u201cat its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration\u2019s Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date.\u201d Following this announcement, the price of the Company\u2019s stock dropped. If you purchased Sarepta Therapeutics stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Marshall Dees, Esq. at\u202f mdees@holzerlaw.com or Joshua Karr, Esq. at\u202fjkarr@holzerlaw.com, call our … Continue reading "Investigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-14T16:00:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODIyMCM1NTI3Mjg2IzIxODA3Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Investigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC\",\"datePublished\":\"2023-04-14T16:00:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\\\/\"},\"wordCount\":269,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwODIyMCM1NTI3Mjg2IzIxODA3Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\\\/\",\"name\":\"Investigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwODIyMCM1NTI3Mjg2IzIxODA3Njc=\",\"datePublished\":\"2023-04-14T16:00:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwODIyMCM1NTI3Mjg2IzIxODA3Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwODIyMCM1NTI3Mjg2IzIxODA3Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/","og_locale":"en_US","og_type":"article","og_title":"Investigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC - Market Newsdesk","og_description":"ATLANTA, April 14, 2023 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether Sarepta Therapeutics, Inc. (\u201cSarepta Therapeutics\u201d\u202for the \u201cCompany\u201d) (NASDAQ: SRPT) complied with federal securities laws. On March 16, 2023, Sarepta Therapeutics announced that \u201cat its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration\u2019s Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date.\u201d Following this announcement, the price of the Company\u2019s stock dropped. If you purchased Sarepta Therapeutics stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Marshall Dees, Esq. at\u202f mdees@holzerlaw.com or Joshua Karr, Esq. at\u202fjkarr@holzerlaw.com, call our … Continue reading \"Investigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-14T16:00:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODIyMCM1NTI3Mjg2IzIxODA3Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Investigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC","datePublished":"2023-04-14T16:00:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/"},"wordCount":269,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODIyMCM1NTI3Mjg2IzIxODA3Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/","name":"Investigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODIyMCM1NTI3Mjg2IzIxODA3Njc=","datePublished":"2023-04-14T16:00:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODIyMCM1NTI3Mjg2IzIxODA3Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODIyMCM1NTI3Mjg2IzIxODA3Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-sarepta-therapeutics-inc-srpt-announced-by-holzer-holzer-llc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Investigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/747811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=747811"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/747811\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=747811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=747811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=747811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}